In an 85-year-old woman with chronic heart failure, COPD, shortness of breath, severe chronic kidney disease (eGFR 16–28 mL/min), hyperkalemia (potassium 5.1–5.5 mmol/L), anemia with low transferrin saturation, secondary hyperparathyroidism, and markedly elevated NT‑proBNP, how should her volume status and guideline‑directed heart‑failure therapy be optimized?

Management of Volume Status and Heart Failure Therapy in This Patient

This patient requires aggressive diuresis with continuous intravenous furosemide infusion while simultaneously addressing her hyperkalemia to enable continuation of guideline-directed medical therapy (GDMT), particularly avoiding potassium-sparing agents given her severe renal dysfunction and elevated potassium.

Immediate Volume Management

The markedly elevated NT-proBNP (33,435 pg/mL) and clinical presentation indicate severe volume overload requiring urgent decongestion. With an eGFR of 16-17 mL/min/1.73m² and diuretic resistance likely, continuous intravenous furosemide infusion is superior to bolus dosing 1. Loop diuretics remain the cornerstone since thiazides are ineffective at GFR <30 mL/min unless used synergistically with loop diuretics 2.

Diuretic Strategy:

• Initiate continuous IV furosemide infusion (more effective than repeated boluses in refractory cases) 1
• If inadequate response, add metolazone for synergistic distal tubular blockade 2
• Monitor daily: weight, urine output, blood pressure, electrolytes, and creatinine 1
• In highly selected cases with persistent volume overload despite maximal medical therapy, ultrafiltration may be considered in consultation with nephrology, particularly effective when renal function is severely but stably impaired 1

Critical caveat: The 30% increase in creatinine (1.74→2.82 mg/dL) represents acute-on-chronic kidney injury. While this typically warrants caution with diuretics, in severe volume overload with elevated filling pressures, aggressive diuresis may paradoxically improve renal function by shifting leftward on the Starling curve 1.

Hyperkalemia Management

The potassium of 5.1-5.5 mmol/L with eGFR 16-17 mL/min/1.73m² absolutely contraindicates potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) 2. Despite aldosterone antagonists being recommended for advanced heart failure (NYHA III-IV) to improve survival 2, this patient's severe renal dysfunction and existing hyperkalemia make them prohibitively dangerous 3, 4.

Hyperkalemia Strategy:

• Avoid all potassium-sparing diuretics 2
• Loop diuretics provide protective effect against hyperkalemia 4
• Consider potassium binders (patiromer or sodium zirconium cyclosilicate) if hyperkalemia persists, allowing continuation of ACE inhibitors/ARBs 5, 6, 7
• Monitor potassium within 1-3 days after any diuretic adjustment in advanced heart failure 1

GDMT Optimization in Severe CKD

ACE Inhibitors/ARBs:

Continue at the lowest effective dose with close monitoring 2. While guidelines recommend avoiding potassium-sparing diuretics during ACE inhibitor initiation 2, established therapy should be continued unless creatinine increases >30% from baseline or hyperkalemia becomes unmanageable 1. Check electrolytes and renal function within 1-2 weeks after any dose adjustment 2.

Beta-Blockers:

Beta-blockers should be continued or initiated once clinically stable 2, 1. They are recommended for all patients with reduced LVEF (40% in this case) in NYHA class II-IV on standard therapy 2. Beta-blockers may reduce diuretic requirements over time as cardiac function improves 1.

Contraindicated Medications:

• Absolutely avoid NSAIDs 2
• Avoid potassium-sparing diuretics (spironolactone, eplerenone) 2
• Avoid excessive diuresis before ACE inhibitor adjustments 2

Anemia Management

The hemoglobin of 9.7-10.3 g/dL with low transferrin saturation (22%) indicates functional iron deficiency requiring treatment 1. Hemoglobin <90-110 g/L is associated with increased heart failure symptoms and adverse events 1.

Anemia Strategy:

• Evaluate and treat iron deficiency (ferritin 118 ng/mL with TSAT 22% suggests functional deficiency) 1, 8
• Check vitamin B12 and folate 1
• Consider intravenous iron (ferric carboxymaltose) given severe heart failure and low TSAT 8, 9
• Blood transfusion may be considered if advanced symptoms persist after substrate correction 1

Monitoring Protocol

Daily while hospitalized:

• Body weight, urine output, blood pressure 1
• Serum electrolytes (especially potassium) and creatinine 1

Within 1-3 days after diuretic intensification:

• Repeat electrolytes and creatinine 1

Within 2-4 weeks after diuretic reduction:

• Recheck potassium (especially with concurrent ACE inhibitor/ARB) 1

Key Clinical Pitfalls

1. Do not withhold loop diuretics despite worsening creatinine when severe volume overload is present—decongestion may improve renal perfusion 1
2. Never add aldosterone antagonists with eGFR <30 mL/min and existing hyperkalemia 2, 3, 4
3. Avoid excessive diuresis before adjusting ACE inhibitors 2
4. Monitor for hypomagnesemia and hypokalemia from chronic loop diuretic use, which can cause diuretic resistance 1
5. Secondary hyperparathyroidism (PTH 109 pg/mL) reflects CKD-mineral bone disorder but does not alter acute heart failure management 10